Novartis' Anti-Seizure Drug New Target Of PL Suit
Already besieged by hundreds of product liability suits surrounding its contentious bone density drugs, Novartis Pharmaceuticals Corp. is now facing a fresh assault over anti-seizure medication Trileptal....To view the full article, register now.
Already a subscriber? Click here to view full article